首页> 外文期刊>Biochimica et biophysica acta. Reviews on cancer >Long non-coding RNAs and nuclear factor-kappa B crosstalk in cancer and other human diseases
【24h】

Long non-coding RNAs and nuclear factor-kappa B crosstalk in cancer and other human diseases

机译:长期非编码RNA和核因子-Kappa-Kappa B癌症和其他人类疾病

获取原文
获取原文并翻译 | 示例
           

摘要

The regulation of the pleiotropic transcription factor, nuclear factor-kappa B (NF-kappa B) by miRNAs and proteins is extensively studied. More recently, the NF-kappa B signaling was also reported to be regulated by several long noncoding RNAs (lncRNAs) that constitute the major portion of the noncoding component of the human genome. The common NF-kappa B associated lncRNAs include NKILA, HOTAIR, MALAT1, ANRIL, Lethe, MIR31HG, and PACER. The lncRNA and NF-kappa B signaling crosstalk during cancer and other diseases such as cardiomyopathy, celiac disease, cerebral infarction, chronic kidney disease, diabetes mellitus, Kawasaki disease, pregnancy loss, and rheumatoid arthritis. Some NE-kappa B related lncRNAs can affect gene expression without modulating NE-kappa B signaling. Most of the lncRNAs with a potential to modulate NF-kappa B signaling are regulated by NF-kappa B itself suggesting a feedback regulation. The discovery of lncRNAs have provided a new type of regulation for the NF kappa B signaling and thus could be explored for therapeutic interventions. The manner in which LncRNA and NF-kappa B crosstalk affects human pathophysiology is discussed in this review. The challenges associated with the therapeutic interventions of this crosstalk are also discussed.
机译:麦克麻类和蛋白质的磷酸术转录因子,核因子-Kappa B(NF-Kappa B)的调节被广泛研究。最近,还报道了NF-Kappa B信令由几个长的非编码RNA(LNCRNA)调节,其构成人类基因组的非编码组分的主要部分。常见的NF-κB相关的LNCRNA包括NKILA,HOTAIR,MALAT1,ANRIL,Lethe,MIR31HG和PAPER。癌症和其他疾病中的LNCRNA和NF-Kappa B信号串扰,如心肌病,乳糜泻,脑梗死,慢性肾病,糖尿病,川崎病,妊娠损失和类风湿性关节炎。一些Ne-Kappa B相关的LNCRNA可以影响基因表达而不调制NE-Kappa B信号。具有调制NF-Kappa B信令的大多数LNCRNA由NF-Kappa B本身调节,表明反馈调节。 LNCRNA的发现已经为NF Kappa B信令提供了一种新的调节,因此可以探索治疗干预措施。在本综述中讨论了LNCRNA和NF-Kappa B串扰影响人病理生理学的方式。还讨论了与这种串扰的治疗干预相关的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号